Clinical efficacy of Ambroxol Combined with Cefoperazone/Sulbactam in the Treatment of Senile COPD with Pulmonary Infection and Its Influence on Inflammatory Factors
Objective To analyse the effects of cefoperazone and sulbactam combined with ambroxol on pulmonary function and levels of inflammatory factors in patients with chronic obstructive pulmonary disease(COPD)combined with pulmonary infection.Methods A total of 70 patients with COPD complicated with pulmonary infection admitted to Xuzhou Mining Hospital from January 2020 to December 2022 were selected as the research objects and divided into two groups according to the random number table method,with 35 cases in each group.The control group was treated with cefoperazone sodium and sulbactam sodium on the basis of conventional treatment,and the combined group was treated with ambroxol on the basis of the control group.The pulmonary function indexes,inflammatory in-dexes and adverse reactions were compared between the two groups.Result The total effective rate of the observation group(94.29%)was higher than that of the control group(77.14%),and the difference was statistically significant(χ²= 4.200,P=0.040).After treatment,the lung function index of the observation group was higher than that of the control group,and the white blood cell count,C-reactive protein,interleukin-6 and interleukin-8 were lower than those of the control group,the differences were statistically significant(all P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Cefoperazone sodium and sulbac-tam sodium combined with ambroxol in the treatment of COPD patients with pulmonary infection is effective,can sig-nificantly improve lung function and inflammatory response,and have good safety.
Chronic obstructive pulmonary diseaseLung infectionAmbroxolCefoperazone and sulbactam
万方数据
维普
